Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Omalizumab biosimilar - Teva Pharmaceutical Industries

Next Previous
Drug Profile

Omalizumab biosimilar - Teva Pharmaceutical Industries

Alternative Names: TEV-45779

Latest Information Update: 19 Jun 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Teva Pharmaceutical Industries
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action IgE receptor antagonists; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Chronic urticaria

Most Recent Events

  • 05 Apr 2024 Teva Pharmaceuticals completes a phase III trial in Chronic-urticaria (Treatment-experienced) in USA, Slovakia, Czech Republic, Poland, Greece and Bulgaria (SC) (NCT04976192) (EudraCT2021-001796-17)
  • 30 Aug 2021 Phase-III clinical trials in Chronic-urticaria (Treatment-experienced) in Slovakia, Czech Republic, Poland, Greece, Bulgaria (SC) (NCT04976192) (EudraCT2021-001796-17)
  • 30 Aug 2021 Phase-III clinical trials in Chronic-urticaria in USA (SC) (NCT04976192)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top